Invivyd (IVVD) Shares Outstanding (Diluted Average) (2021 - 2025)
Invivyd (IVVD) reported Shares Outstanding (Diluted Average) of $172.2 million for Q4 2025, up 45.26% on a YoY basis from $118.6 million in Q4 2024, and up 1.2% quarter-over-quarter from $170.2 million in Q3 2025.
Invivyd (IVVD) Shares Outstanding (Diluted Average) (2021 - 2025) Analysis & Trends
Invivyd has reported Shares Outstanding (Diluted Average) for 5 years, with the latest figure at $172.2 million in Q4 2025.
- For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 45.26% year-over-year to $172.2 million; the trailing twelve-month figure through Dec 2025 stood at $172.2 million (up 45.26% YoY), and the FY2025 full-year result was $172.2 million, up 45.26% from the prior year.
- Shares Outstanding (Diluted Average) for Q4 2025 stood at $172.2 million, up from $170.2 million in the prior quarter.
- The five-year high for Shares Outstanding (Diluted Average) was $172.2 million in Q4 2025, with the low at $249769.0 in Q2 2021.
- Historically, Shares Outstanding (Diluted Average) has averaged $106.8 million across 5 years, with a median of $109.5 million in 2023.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Diluted Average) surged 43147.58% — and 2025, when it grew 0.55%.
- Invivyd's Shares Outstanding (Diluted Average) stood at $42.6 million in 2021, then jumped by 154.02% to $108.3 million in 2022, then rose by 1.16% to $109.5 million in 2023, then gained by 8.24% to $118.6 million in 2024, then soared by 45.26% to $172.2 million in 2025.
- The last three Shares Outstanding (Diluted Average) figures came in at $172.2 million (Q4 2025), $170.2 million (Q3 2025), and $120.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Invivyd | 168.41 Mn | -58.28 Mn | - | 172.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 172.21 Mn |
| Sep 30, 2025 | 170.17 Mn |
| Jun 30, 2025 | 120.02 Mn |
| Mar 31, 2025 | 119.88 Mn |
| Dec 31, 2024 | 118.56 Mn |
| Sep 30, 2024 | 119.50 Mn |
| Jun 30, 2024 | 119.36 Mn |
| Mar 31, 2024 | 115.62 Mn |
| Dec 31, 2023 | 109.53 Mn |
| Sep 30, 2023 | 109.75 Mn |
| Jun 30, 2023 | 109.45 Mn |
| Mar 31, 2023 | 108.79 Mn |
| Dec 31, 2022 | 108.27 Mn |
| Sep 30, 2022 | 108.15 Mn |
| Jun 30, 2022 | 108.02 Mn |
| Mar 31, 2022 | 107.87 Mn |
| Dec 31, 2021 | 42.62 Mn |
| Sep 30, 2021 | 61.30 Mn |
| Jun 30, 2021 | 249,769.00 |